Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DDMAC Adds New Consumer Group To Handle Ad Load; More Marketing Briefs

Executive Summary

A fresh look at DTC: CDER's Division of Drug Marketing, Advertising & Communication is creating a second direct-to-consumer review group to address the ad division's growing review burden. "It's just important to try to address the increased workload that we're getting and to have two group leaders to help to make sure that our advisory comments to you are not getting bottlenecked somewhere," DTC Review Group Leader Melissa Moncavage says at FDLI's Sept. 18-19 advertising and promotion conference. The DTC review groups will be led by Moncavage and Lead Consumer Safety Officer Christine Smith, effective immediately. DDMAC will retain its four review groups to evaluate professional advertising. Funding to help meet DDMAC's workload, which has increased with the PhRMA guideline's recommendation for DTC preclearance, has come up in PDUFA negotiations...

You may also be interested in...



Pfizer’s Lipitor Ad Campaign Is A Cautionary Tale For Industry

Controversy surrounding Pfizer's direct-to-consumer advertisements for Lipitor spotlight the inherent risks manufacturers continue to face when launching ad campaigns

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest News
See All
UsernamePublicRestriction

Register

PS047591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel